Recent developments in antimicrobial therapy for gastrointestinal infections

Travis J. Carlson; Anne J. Gonzales-Luna; Kevin W. Garey

doi:10.1097/MOG.0000000000000696

Recent developments in antimicrobial therapy for gastrointestinal infections

Travis J. Carlson, Anne J. Gonzales-Luna, Kevin W. Garey

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Purpose of reviewThis focused, narrative review summarizes human clinical trial data for direct-acting antimicrobials in development for the treatment of gastrointestinal infections that were published in the past 18 months (1 January 2019 to 30 June 2020).Recent findingsAntimicrobial agents for Clostridioides difficile infection (n = 6), cryptosporidiosis (n = 1), cytomegalovirus infection (n = 3) and Helicobacter pylori infection (n = 1) have completed and/or are undergoing human clinical trials.SummaryAlthough this review highlights significant advances in four disease states, many common gastrointestinal pathogens have no antimicrobials in human clinical trials, emphasizing the need for continued prioritization in this field of study.

Original language	English (US)
Pages (from-to)	30-36
Number of pages	7
Journal	Current Opinion in Gastroenterology
Volume	37
Issue number	1
DOIs	https://doi.org/10.1097/MOG.0000000000000696
State	Published - Jan 1 2021
Externally published	Yes

Keywords

Clostridioides difficile
Clostridium difficile
cryptosporidium
cytomegalovirus
diarrhea
gastroenteritis
gastrointestinal infections
Helicobacter pylori

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1097/MOG.0000000000000696

Cite this

@article{db8c7636572a4b7e8ca14bab3dde8fcc,

title = "Recent developments in antimicrobial therapy for gastrointestinal infections",

abstract = "Purpose of reviewThis focused, narrative review summarizes human clinical trial data for direct-acting antimicrobials in development for the treatment of gastrointestinal infections that were published in the past 18 months (1 January 2019 to 30 June 2020).Recent findingsAntimicrobial agents for Clostridioides difficile infection (n = 6), cryptosporidiosis (n = 1), cytomegalovirus infection (n = 3) and Helicobacter pylori infection (n = 1) have completed and/or are undergoing human clinical trials.SummaryAlthough this review highlights significant advances in four disease states, many common gastrointestinal pathogens have no antimicrobials in human clinical trials, emphasizing the need for continued prioritization in this field of study.",

keywords = "Clostridioides difficile, Clostridium difficile, cryptosporidium, cytomegalovirus, diarrhea, gastroenteritis, gastrointestinal infections, Helicobacter pylori",

author = "Carlson, {Travis J.} and Gonzales-Luna, {Anne J.} and Garey, {Kevin W.}",

year = "2021",

month = jan,

day = "1",

doi = "10.1097/MOG.0000000000000696",

language = "English (US)",

volume = "37",

pages = "30--36",

journal = "Current Opinion in Gastroenterology",

issn = "0267-1379",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Recent developments in antimicrobial therapy for gastrointestinal infections

AU - Carlson, Travis J.

AU - Gonzales-Luna, Anne J.

AU - Garey, Kevin W.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Purpose of reviewThis focused, narrative review summarizes human clinical trial data for direct-acting antimicrobials in development for the treatment of gastrointestinal infections that were published in the past 18 months (1 January 2019 to 30 June 2020).Recent findingsAntimicrobial agents for Clostridioides difficile infection (n = 6), cryptosporidiosis (n = 1), cytomegalovirus infection (n = 3) and Helicobacter pylori infection (n = 1) have completed and/or are undergoing human clinical trials.SummaryAlthough this review highlights significant advances in four disease states, many common gastrointestinal pathogens have no antimicrobials in human clinical trials, emphasizing the need for continued prioritization in this field of study.

AB - Purpose of reviewThis focused, narrative review summarizes human clinical trial data for direct-acting antimicrobials in development for the treatment of gastrointestinal infections that were published in the past 18 months (1 January 2019 to 30 June 2020).Recent findingsAntimicrobial agents for Clostridioides difficile infection (n = 6), cryptosporidiosis (n = 1), cytomegalovirus infection (n = 3) and Helicobacter pylori infection (n = 1) have completed and/or are undergoing human clinical trials.SummaryAlthough this review highlights significant advances in four disease states, many common gastrointestinal pathogens have no antimicrobials in human clinical trials, emphasizing the need for continued prioritization in this field of study.

KW - Clostridioides difficile

KW - Clostridium difficile

KW - cryptosporidium

KW - cytomegalovirus

KW - diarrhea

KW - gastroenteritis

KW - gastrointestinal infections

KW - Helicobacter pylori

UR - http://www.scopus.com/inward/record.url?scp=85097210735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097210735&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000696

DO - 10.1097/MOG.0000000000000696

M3 - Review article

C2 - 33229860

AN - SCOPUS:85097210735

SN - 0267-1379

VL - 37

SP - 30

EP - 36

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

IS - 1

ER -

Recent developments in antimicrobial therapy for gastrointestinal infections

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this